| ID Source | ID |
|---|---|
| PubMed CID | 123318 |
| CHEBI ID | 48141 |
| MeSH ID | M0165422 |
| Synonym |
|---|
| disiloxane |
| 13597-73-4 |
| CHEBI:48141 |
| disiloxan |
| h3si-o-sih3 |
| oxybis(silane) |
| silyloxysilane |
| bis-silyl ether |
| bis silyl ether |
| KPUWHANPEXNPJT-UHFFFAOYSA-N |
| mono-silyl ether |
| silylether |
| Q2675470 |
| h3 si o si h3 |
| Class | Description |
|---|---|
| siloxane | Siloxanes are saturated silicon-oxygen hydrides with unbranched or branched chains of alternating silicon and oxygen atoms (each silicon atom is separated from its nearest silicon neighbours by single oxygen atoms). By extension hydrocarbyl derivatives are commonly included. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (4.55) | 18.7374 |
| 1990's | 1 (4.55) | 18.2507 |
| 2000's | 4 (18.18) | 29.6817 |
| 2010's | 10 (45.45) | 24.3611 |
| 2020's | 6 (27.27) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 22 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Article | Year |
|---|---|
| A Novel, Nonpeptidic, Orally Active Bivalent Inhibitor of Human β-Tryptase. Pharmacology, Volume: 102, Issue: 5-6 | 2018 |
| [information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | |